Study title:
Vecchi-V, Pileri-S, Burnelli-R, Bontempi-N, Comelli-A, Testi-A-M, Carli-M, Sotti-G, Rosati-D, Di-Tullio-M-T, et al.
III Department of Pediatrics, Bologna University, Italy.
Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients.
Cancer, {Cancer}, 15 Sep 1993, vol. 72, no. 6, p. 2049-57, ISSN: 0008-543X.Vecchi-V, Pileri-S, Burnelli-R, Bontempi-N, Comelli-A, Testi-A-M, Carli-M, Sotti-G, Rosati-D, Di-Tullio-M-T, et al.
III Department of Pediatrics, Bologna University, Italy.
Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients.
Cancer, {Cancer}, 15 Sep 1993, vol. 72, no. 6, p. 2049-57, ISSN: 0008-543X.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: PROCARBAZINE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|